4.4 Article

National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 2

期刊

JOURNAL OF CLINICAL LIPIDOLOGY
卷 9, 期 6, 页码 S1-S122

出版社

ELSEVIER SCIENCE INC
DOI: 10.1016/j.jacl.2015.09.002

关键词

Clinical recommendations; Dyslipidemia; Lifestyle therapies; Children; Elderly; Human immunodeficiency virus; Rheumatoid arthritis; Residual risk; Adherence; Team-based care

资金

  1. Merck and Co
  2. Amarin
  3. Amgen
  4. AstraZeneca
  5. Regeneron/Sanofi-Aventis
  6. AbbVie
  7. Matinas BioPharma
  8. Pharmavite
  9. Sancilio Co.
  10. DuPont
  11. ACH Foods
  12. Shaklee
  13. Egg Nutrition Center
  14. National Dairy Council
  15. National Cattlemen's Beef Association
  16. Hershey Foods and Almond Board of CA
  17. Solae/DuPont
  18. California Strawberry Commission
  19. California Walnut Commission
  20. Ag Canada
  21. Canola Oil Council
  22. Ocean Spray Cranberries
  23. Merck Sharpe Dohme
  24. Novo Nordisk Inc.
  25. Arena Pharmaceuticals
  26. Boehringer Ingelheim
  27. Cargill Inc
  28. GlaxoSmithKline
  29. Novo Nordisk
  30. Orexigen Therapeutics
  31. Shionogi
  32. Takeda
  33. Stratum Nutrition
  34. California Raisin Board
  35. Esperion
  36. Essentialis
  37. Forest
  38. Gilead Sciences Inc
  39. Given
  40. Hoffman-LaRoche
  41. Home Access
  42. Novartis
  43. Sanofi-Aventis
  44. Otsuka
  45. Janssen
  46. Merck
  47. Omthera
  48. Pfizer
  49. Trygg Pharmaceuticals
  50. TWI Bio
  51. Xoma
  52. Ardea Inc
  53. High Point Pharmaceuticals LLC
  54. Micropharma Limited
  55. Trans Tech Pharma Inc
  56. TIMI
  57. Pozen
  58. Regeneron
  59. Elcelyx
  60. Bristol-Myers Squibb
  61. Catabasis
  62. Daiichi-Sankyo Inc
  63. Eisai
  64. Merck Co
  65. VIVUS
  66. Zeomedex
  67. WPU
  68. Akcea
  69. Genzyme
  70. Pfizer Inc.
  71. Medtelligence
  72. Vindico

向作者/读者索取更多资源

An Expert Panel convened by the National Lipid Association previously developed a consensus set of recommendations for the patient-centered management of dyslipidemia in clinical medicine (part 1). These were guided by the principle that reducing elevated levels of atherogenic cholesterol (non high-density lipoprotein cholesterol and low-density lipoprotein cholesterol) reduces the risk for atherosclerotic cardiovascular disease. This document represents a continuation of the National Lipid Association recommendations developed by a diverse panel of experts who examined the evidence base and provided recommendations regarding the following topics: (1) lifestyle therapies; (2) groups with special considerations, including children and adolescents, women, older patients, certain ethnic and racial groups, patients infected with human immunodeficiency virus, patients with rheumatoid arthritis, and patients with residual risk despite statin and lifestyle therapies; and (3) strategies to improve patient outcomes by increasing adherence and using team-based collaborative care. (C) 2015 National Lipid Association. Published by Elseiver Inc.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据